The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon
E-337, EAST OF KAILASH, NEW DELHI 110065, INDIA
Tel:
Work +91 11 46667000
Email:
Web:
www.singhassociates.in

Gunita Pahwa

Tel:
Work 91-11-46667000
Email:
Singh & Associates Founder – Manoj K Singh Advocates and Solicit

Work Department

Contract &Transactions Practice Group

Position

Senior Partner
Head -  Contract &Transactions Practice Group

Languages

English, Hindi


India

Corporate and M&A

Within: Corporate and M&A

Singh & Associates Founder – Manoj K Singh Advocates and Solicitors advises domestic and international clients on company formations and tax structuring, mergers and acquisitions, due diligence and regulatory approvals. The group recently advised The Leschaco Group on a share purchase agreement with Escombe Lambert, and also assisted Udayan Care with various issues surrounding governance structure, board policies and appraisal mechanisms, among other matters. Gunita Pahwa heads the transactional practice, and Daizy Chawla is the key contact for corporate and taxation issues.

[back to top]

Labour and employment

Within: Labour and employment

Led by Gunita Pahwa and Daizy Chawla, the team at Singh & Associates Founder – Manoj K Singh Advocates and Solicitors advises on state and central labour and employment law, internal disciplinary proceedings, disputes, regulatory compliance issues, contracts, and legal notices. Clients include Era Infra Engineering, FircoSoft and Clinipace Worldwide.

[back to top]

Tax

Within: Tax

At Singh & Associates Founder – Manoj K Singh Advocates and Solicitors, Daizy Chawla represented Dunar Foods in an excise matter before the Supreme Court. Gunita Pahwa is another key name. Henry Ford Health System is also a client.

[back to top]


Back to index

Legal Developments by:
Singh & Associates Founder – Manoj K Singh Advocates and Solicit

  • BRAND-JACKING

    WHAT IS BRANDJACKING?
    - Singh & Associates Founder – Manoj K Singh A

Legal Developments in India

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to
  • Sulphur Cap Ahead - Regulatory

    Sulphur Cap Ahead - Regulatory
  • GTDT Shipping - India

    Mr Shardul Thacker heads the shipping, oil and gas and banking practice group at Mulla & Mulla & Craigie Blunt & Caroe. Lloyd’s List ranked him third in their top 10 lawyers stating: “Highly regarded for his work in the liquefied natural gas sector, particularly for interesting and highly geared finance deals in relation to infrastructure projects, energy, ports and ships.” india_-_gtdt_shipping_
  • Chambers Guides - Insurance 2018 - India

    India is a common-law jurisdiction. In general, Indian laws borrow heavily from, and are based on, English law. However, insurance law in India has certain unique features that deviate from English insurance law. The primary legislation of insurance law in India is the Insurance Act, 1938 (the “Insurance Act”) and the Insurance Rules, 1939 (the “Insurance Rules”).
  • Transport Finance Review - India

    The transportation industry – aviation, shipping and rail – has been predominantly owned by government entities since India’s independence in 1947. Air India and Indian Airlines, both government-owned, rules the skies; the Shipping Corporation of India (SCI), established in 1961 and owned by the government, owns and operates around one-third of the Indian tonnage. All railway property is government owned.
  • International Arbitration Review - India

    The Arbitration and Conciliation Act, 1996 (Act) provides the framework for arbitration and conciliation in India. Drafted on the basis of the UNCITRAL Model Law, it is divided into four parts. Each part governs a different aspect of the arbitration and conciliation process: a Part 1 governs commercial arbitration; b Part 2 governs the enforcement of certain foreign awards; c Part 3 governs conciliation; and d Part 4 contains supplementary provisions (regarding the power of the court to make rulings, etc.). The Act 2 was recently amended in 2016 with an aim to make it more robust by plugging the lacunae that existed in the original legislation.
  • ICLG Shipping law 2018 - India

    In the event of a collision, grounding or other major casualty, what are the key provisions that will impact upon the liability and response of interested parties? In particular, the relevant law / conventions in force in relation to:
  • India - Chambers Guides - Shipping 2018

    The ‘Law & Practice’ sections provide easily accessible information on navigating the legal system when conducting business in the jurisdiction. Leading lawyers explain local law and practice at key transactional stages and for crucial aspects of doing business.
  • BRAND-JACKING

    WHAT IS BRANDJACKING?
  • Post Marketing Surveillance of Drugs

    Post marketing surveillance is performed after market approval/clinical trials of drugs in India. The regulatory framework for conducting clinical trials of drugs is provided under the Drugs and Cosmetics Act, 1940 (“ Act ”) and the Drugs and Cosmetics Rules, 1945 (“ Rules ”). Further, Part X-A and Schedule Y of the Rules specifically deal with the statutory provisions applicable for clinical trial of drugs in India. Schedule Y divides Clinical trial of drugs into 4 Phases, namely, Human Pharmacology (Phase-I), Therapeutic exploratory trials (Phase-II), Therapeutic confirmatory trials (Phase III) and Post Marketing Trials (Phase-IV).
  • Protection of Biotechnology under Indian Laws

    According to the eighth annual survey conducted by the Association of Biotechnology-Led Enterprises (ABLE) and Bio Spectrum, the Indian biotech industry grew threefold in just five years to report revenues of US$ 3 billion in 2009-10, a rise of 17 per cent over the previous year. Maintaining the momentum of the previous years, the Indian biotech industry grew 16.28 per cent in FY2014; the total industry size was US$ 5 billion at the end of the financial year and it reached US$ 7 billion in FY2015. Fast-paced growth is likely to continue; the industry is expected to increase in size to USD11.6 billion by 2017, driven by a range   of factors such as growing demand, intensive R & D activities and strong government initiatives ( http://www.ibef.org/industry/biotechnology-india.aspx )